Along with gain- and loss-of-function animal models, studies using FXR, TGR5 and dual agonists support a beneficial effect in NAFLD and its dysmetabolic context [17,19,20]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.